Drug class
Tau-targeted fluorine-18 radiopharmaceutical; diagnostic PET imaging agent
Mechanism of action
Binds to aggregated tau protein in the brain, including tau neurofibrillary tangles. After intravenous administration it crosses the blood-brain barrier and accumulates in regions containing tau aggregates; fluorine-18 positron emissions permit PET visualisation.
General use cases
- PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary-tangle pathology, under the US TAUKLARIFY product indication.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
